Bio Products Laboratory

Michael Burns Joins Invizyne as Executive Vice President of Energy Transition

Retrieved on: 
Wednesday, November 8, 2023
Carbon, Bryant University, Energy transition, U.S. Department of Energy, Office of Inspector General, Bio Products Laboratory, Enzyme, BASF, Aviation, Nature Communications, Western New England University, U.S. Department of Defense Strategy for Operating in Cyberspace, Synthetic biology, Verenium Corporation, MDB, Renewable energy, Novozymes

Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") ­– today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.

Key Points: 
  • Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") ­– today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.
  • "Michael Burns brings two decades worth of business strategy and development, global licensing, project development, and project finance expertise in the sustainable energy and synthetic biology industries to Invizyne.
  • We are honored to have an executive with his gravitas and experience join the team to head up our new Energy Transition business unit,” said Mo Hayat, CEO of Invizyne.
  • He also served in strategy and development roles at Verenium Corporation, a specialized enzyme biotechnology company that was acquired by BASF.

KEDPLASMA Announces Nationwide Facility Remodeling Project

Retrieved on: 
Wednesday, November 1, 2023
Plasma, Bio Products Laboratory, Collection, Patient, BPL, Heart, Pharmaceutical industry

In 2022, Kedrion Biopharma and UK-based Bio Products Laboratory joined forces, adding BPL's 29 plasma collection centers to the centers operated by KEDPLASMA.

Key Points: 
  • In 2022, Kedrion Biopharma and UK-based Bio Products Laboratory joined forces, adding BPL's 29 plasma collection centers to the centers operated by KEDPLASMA.
  • As a result, the company will temporarily close several of its BPL-branded locations for remodeling and facility enhancement.
  • Stough Development Corporation will partner with KEDPLASMA on the project.
  • KEDPLASMA will consistently update its website ( https://www.kedplasma.us / ) with the latest information on the remodeling progress and reopening dates.

Global Plasma Fractionation Market Valued at $5 Billion in 2023, Expected to Surge with 10% CAGR by 2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Health, Pharmaceutical, Government, Partnership, COVID-19, Pharmacy, Prevalence, CSL, Therapy, Primary immunodeficiency, Ageing, Protease, Rare, Takeda Pharmaceutical Company, Type, Antibody, Collection, Bio Products Laboratory, Growth, Takeda, BPL, Patient, Albumin, Blood product, Rare-earth element, Pharmaceutical industry, Sintering, Grifols, Plasma

The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.

Key Points: 
  • The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.
  • Plasma Collection Centers in the US: Currently, the United States is home to approximately 80% of the world's plasma donation centers.
  • The country supplies over 70% of the plasma used in the manufacturing of plasma-derived therapies through the process of plasma fractionation.
  • Importance of Plasma Fractionation: Plasma fractionation is a critical process for separating and purifying key blood plasma components, including immunoglobulins, albumins, anticoagulant factors, and protease inhibitors.

Parenteral Drug Association and Euromed Communications release Industrial Pharmaceutical Microbiology Under New Collaboration

Retrieved on: 
Monday, September 25, 2023
FIP, Partnership, Book, Education, RPS, ABPI, Parenteral Drug Association, Multimedia, Science, PDA, EMA, Bio Products Laboratory, Publishing, Publication, Patient, Federation, Royal Pharmaceutical Society, FDA, EC, MHRA, Pharmaceutical industry

BETHESDA, Md., Sept. 25, 2023 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Standards & Controls (Sixth Edition), edited by Tim Sandle of Bio Products Laboratory, UK. This 700-page volume includes 25 chapters from 20 authors. Electronic copies are sold by both PDA and Euromed Communications and hardcopies exclusively by the latter company.

Key Points: 
  • BETHESDA, Md., Sept. 25, 2023 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Standards & Controls (Sixth Edition), edited by Tim Sandle of Bio Products Laboratory, UK.
  • Electronic copies are sold by both PDA and Euromed Communications and hardcopies exclusively by the latter company.
  • To learn more about this title and/or to purchase it, click here to the PDA Bookstore or the Euromed Communications store .
  • Over the years EC has built up close associations with various international pharmaceutical organisations such as the Royal Pharmaceutical Society (RPS), the Association of British Pharmaceutical Industries (ABPI), and the Federation of Industrial Pharmacists (FIP).

ImmunoTek Bio Centers Welcomes New President

Retrieved on: 
Monday, April 3, 2023
Medical Supplies, Health, United States service academies, Parnell, Bio Products Laboratory, University, System, BPL, Dyke, Systems engineering, Business, Thermo Fisher Scientific, Plasma, Business administration, Growth, Master of Business Administration, Management, Economics

ImmunoTek Bio Centers LLC has hired Marvin Dyke as President.

Key Points: 
  • ImmunoTek Bio Centers LLC has hired Marvin Dyke as President.
  • Dyke comes to ImmunoTek with solid experience in the plasma industry, having served six years with Bio-Products Laboratory (BPL) in a variety of executive roles and, most recently, as President of BPL Plasma.
  • In the president role within ImmunoTek, Dyke will be responsible for growing the existing core business of developing plasma centers for customers and expanding the company's industry footprint as a direct supplier to fractionation companies, all while ensuring ImmunoTek maintains its impressive regulatory track record.
  • Some of Dyke’s notable contributions while at BPL Plasma include the development of 20 new plasma centers; the divestiture of 25 centers to a major fractionator, and the divestiture of BPL Plasma to its current owner in 2022.

CSI Pharmacy Announces Limited Distribution Agreement for Gammaplex

Retrieved on: 
Thursday, March 30, 2023
Pharmacy, Doctor of Pharmacy, NASH, BPL, Antibody, Pharmacist, Accreditation Commission for Health Care, Plasma, Bio Products Laboratory, Patient, ACHC, URAC, FDA, CSI, Hospital

NASH, Texas, March 30, 2023 /PRNewswire/ -- CSI Pharmacy, LLC, an independent, national specialty pharmacy and home infusion provider, today announced an agreement with Bio Products Laboratory (BPL) for limited distribution rights to its immune globulin product Gammaplex®.

Key Points: 
  • NASH, Texas, March 30, 2023 /PRNewswire/ -- CSI Pharmacy, LLC, an independent, national specialty pharmacy and home infusion provider, today announced an agreement with Bio Products Laboratory (BPL) for limited distribution rights to its immune globulin product Gammaplex®.
  • Access to Gammaplex means CSI Pharmacy is now able to dispense all FDA-approved immune globulin products.
  • CSI Pharmacy is a national specialty pharmacy dedicated to serving patients with chronic and rare illnesses.
  • Today, CSI Pharmacy is licensed to dispense in 48 states, plus D.C., and is accredited by two of the nation's leading specialty pharmacy accrediting bodies: the Accreditation Commission for Health Care (ACHC) and URAC.

Plasma Fractionation Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 9, 2022
HYCON, Virus, Disease, CSL Limited, Shire (pharmaceutical company), Immune system, Antibody, Conditional sentence, Plasma, Glycoprotein, Takeda Pharmaceutical Company, Chronic condition, Hematology, Patient, Prevalence, Cancer, Immunodeficiency, Critical care, Bio Products Laboratory, Hospital, Takeda, Coagulopathy, Degenerative disease, LFB, Neurology, Diabetes, World Health Organization, Quality of life, Green Cross, COVID-19, Rheumatology, Inflammation, Growth, Octapharma, Death, Protease, B cell, Organization, Acquisition, Baxter International, Pharmaceutical industry, Lithium, Fine chemical, Blood product, Renewable energy, Takeda Oncology

The plasma fractionation market is expected to grow to $35.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.26%.

Key Points: 
  • The plasma fractionation market is expected to grow to $35.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.26%.
  • The plasma fractionation market consists of sales of plasma fractionation by entities (organizations, sole traders, and partnerships) that are used in the manufacture of essential pharmaceutical products that are used to treat immune deficiencies or bleeding disorders.Plasma fractionation refers to the process of separating the various components of blood plasma.
  • The regions covered in plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The plasma fractionation market research report is one of a series of new reports that provides plasma fractionation market statistics, including plasma fractionation industry global market size, regional shares, competitors with an plasma fractionation market share, detailed plasma fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the plasma fractionation industry.

Worldwide Immunoglobulin Industry to 2028 - Prevalence of Immunodeficiency Diseases and Autoimmune Disorders is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022
Health, Pharmaceutical, IVIG, CSL Behring, Antibody, Takeda Pharmaceutical Company, Hematology, Prevalence, Degenerative disease, Research, Bio Products Laboratory, Incidence, US Foods, Growth, Octapharma, Pfizer, Marketing, Pharmaceutical industry

This report suggests that the global immunoglobulin market would exhibit an uptrend trend at a CAGR of 6.77% over the forecast period of 2022-2028.

Key Points: 
  • This report suggests that the global immunoglobulin market would exhibit an uptrend trend at a CAGR of 6.77% over the forecast period of 2022-2028.
  • The market's growth is supported by driving forces like the increase in the global geriatric population, increasing incidence of age-related diseases, the prevalence of autoimmune disorders, increase in research & development activities and prevalence of immunodeficiency diseases.
  • In contrast, the high price associated with immunoglobulin therapy and the high risk of side effects due to its use are the factors that can challenge the market's growth.
  • In addition, due to the increased incidence of various diseases in the United States and Canada, the immunoglobulin market presents an opportunity for increased use of immunoglobulin.

Kedrion strengthens its network of plasma collection centers

Retrieved on: 
Tuesday, December 6, 2022
EPA, Czech Association of Bandy, United Kingdom, Patient, Immunodeficiency, Collection, Bio Products Laboratory, Czech Republic, BPL, Acquisition, Lithium, Plasma

LUCCA, Italy, Dec. 6, 2022 /PRNewswire/ -- Kedrion, a global biopharmaceutical company headquartered in Italy that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating serious diseases and conditions, has announced the acquisition of Czech companies UNICAplasma s.r.o and UNICAplasma Morava s.r.o., which operate five plasma collection centers in the Czech Republic.

Key Points: 
  • We believe that this acquisition will greatly enhance the value of our company - stated Paolo Marcucci, Kedrion Chairman and CEO - allowing us to become a player in the collection of plasma in Europe.
  • We are very proud to add these new companies to the Kedrion group - added Paolo Marcucci - and we welcome all new employees into our corporate family.
  • Mr. Maly is also the founder and the chairperson of the Czech Association of Plasma and chairman of the European Plasma Alliance (EPA), the European plasma collectors association.
  • Kedrion is a biopharmaceutical company founded in Italy that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating patients suffering from Hemophilia, Primary Immunodeficiencies and other serious illnesses.

Kedrion strengthens its network of plasma collection centers

Retrieved on: 
Tuesday, December 6, 2022
EPA, Czech Association of Bandy, United Kingdom, Patient, Immunodeficiency, Collection, Bio Products Laboratory, Czech Republic, BPL, Acquisition, Lithium, Plasma

LUCCA, Italy, Dec. 6, 2022 /PRNewswire/ -- Kedrion, a global biopharmaceutical company headquartered in Italy that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating serious diseases and conditions, has announced the acquisition of Czech companies UNICAplasma s.r.o and UNICAplasma Morava s.r.o., which operate five plasma collection centers in the Czech Republic.

Key Points: 
  • We believe that this acquisition will greatly enhance the value of our company - stated Paolo Marcucci, Kedrion Chairman and CEO - allowing us to become a player in the collection of plasma in Europe.
  • We are very proud to add these new companies to the Kedrion group - added Paolo Marcucci - and we welcome all new employees into our corporate family.
  • Mr. Maly is also the founder and the chairperson of the Czech Association of Plasma and chairman of the European Plasma Alliance (EPA), the European plasma collectors association.
  • Kedrion is a biopharmaceutical company founded in Italy that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating patients suffering from Hemophilia, Primary Immunodeficiencies and other serious illnesses.